Please assess the completion status of the following clinical trial:

Trial Title: Influenza Immunity in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Age~  * Between 6 and 12 months to participate in the vaccination arm of cohort 1 (cohort 1A)~ * Between 3 and 12 months to participate in the natural infection arm of cohort 1 (cohort 1B)~ * Between 13 and 35 months of age to participate in either the vaccination or natural infection arm of cohort 2~ * Between 36 months and 5 years of age to participate in either the vaccination or natural infection arm of cohort 3~ * Between 6 years and 8 years of age to participate in either the vaccination or natural infection arm of cohort 4~* Gestational age of ≥37 weeks at birth~* Parent/guardian can provide informed consent~* Available for the duration of the study~* History of previous IIV administration ONLY for participation in the vaccination arm of cohorts 2, 3, or 4~* Acute illness documented to be due to influenza virus ONLY for participation in the natural infection arms of cohorts 1-4~Exclusion Criteria:~* Immunosuppression as a result of an underlying illness or condition (including HIV or a primary immunodeficiency syndrome)~* Active neoplastic disease~* Use of potentially immunosuppressive medications currently or within the past year (including chemotherapeutic agents) or chronic (\>2 weeks) use of oral or inhaled steroid therapy~* A diagnosis of asthma requiring chronic controller medication~* Previous administration of influenza vaccine in the current influenza season ONLY for subjects receiving an influenza vaccination~* Receipt of immunoglobulin or another blood product within the year prior to study enrollment~* An acute illness within the previous 3 days or temperature \>38o on screening EXCEPT for participation in the natural infection arms of cohorts 1-4~* A contraindication to influenza vaccination EXCEPT infants between 3 and 5 months presenting with natural influenza infection whose only contraindication is their current age

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 8 Years
- Healthy Volunteers: t

Study Arms:
- 6-12 months Seasonal IIV (Type: EXPERIMENTAL): Children 6 - 12 months of age vaccinated with seasonal IIV
- 3-12 months natural infection (Type: EXPERIMENTAL): Children 3-12 months of age presenting with natural influenza infection
- 13-35 months Seasonal IIV (Type: EXPERIMENTAL): Children 13-35 months of age vaccinated with seasonal IIV
- 13-35 months natural infection (Type: EXPERIMENTAL): Children 13-35 months of age presenting with natural influenza infection
- 3-5 years Seasonal IIV (Type: EXPERIMENTAL): Children 3-5 years of age vaccinated with seasonal IIV
- 3-5 years natural infection (Type: EXPERIMENTAL): Children 3-5 years of age presenting with natural influenza infection
- 6-8 years Seasonal IIV (Type: EXPERIMENTAL): Children 6-8 years of age vaccinated with seasonal IIV
- 6-8 years natural infection (Type: EXPERIMENTAL): Children 6-8 years of age presenting with natural influenza infection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete